Immunic\, Inc. Reports that IMU-838\, a Selective Oral DHODH Inhibitor\, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients